TOKYO, Mar 26 (Pulse News Wire) – Ribomic INC. (4591.T) announced today the signing of a joint research agreement with Nissan Chemical Industries Ltd.
The collaboration aims to apply RiboMics' DDS aptamer technology to Nissan Chemical's proprietary nucleic acid technology, focusing on developing foundational technologies for pharmaceuticals targeting central nervous system diseases. Under the agreement, Nissan Chemical will provide certain compensation to RiboMics based on the progress of the research. Nissan Chemical, headquartered in Tokyo, Chuuou Ku Nihonbashi Ni Choume, operates in functional materials, agricultural chemicals, general chemicals, and healthcare sectors. Founded on February 28, 1887, the company has a capital of ¥18.94 billion. Major shareholders include Nippon Mitsubishi UFJ Trust & Banking Corp. (24.67%), Sumitomo Mitsui Trust Bank Ltd.
(11.85%), Mizuho Trust & Banking Co. (4.05%), Nissan Chemical Industry Employee Shareholding Association (2.76%), State Street Corporation (1.42%), Meiji Yasuda Life Insurance Company (1.38%), JP Morgan Chase Bank (385,781), and Sompo Japan Insurance Inc. (1.15%). Recent consolidated financial performance shows that Nissan Chemical had total assets of ¥298.8 billion, ¥323.5 billion, and ¥330.8 billion for fiscal years ending March 2023, 2024, and 2025 respectively. Operating profit was reported at ¥52.28 billion, ¥48.20 billion, and ¥56.83 billion for those same periods. Research activities under the agreement are set to commence on April 01, 2026.
According to the company, there will be no impact on RiboMics' fiscal year 2026 earnings due to this collaboration.
🟢 Confidence: High AI-translated content.